10-Q: Omeros Reports Strong Q2 2026 with YARTEMLEA Sales Growth

Omeros Corporation's Q2 2026 Form 10-Q highlights robust YARTEMLEA sales growth and positive pipeline advancements, alongside a significant repurchase of convertible notes.

Summary

• Omeros Corporation reported net income of $13.2 million for the three months ended June 30, 2026, a significant improvement from a net loss of $25.4 million in the same period last year.
• Product sales, net for YARTEMLEA reached $28.5 million for the three months ended June 30, 2026, indicating strong early commercial performance.
• The company repurchased approximately $30.5 million aggregate principal amount of its 2029 Notes in June and July 2026 for $60.2 million.
• Research and development expenses decreased to $13.8 million from $22.0 million in the prior year period, largely due to the sale of zaltenibart.
• Selling, general, and administrative expenses increased to $13.9 million from $10.3 million, driven by the build-out of the U.S. commercial organization for YARTEMLEA.
• As of June 30, 2026, Omeros had $132.0 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as cautiously optimistic, reflecting significant progress in commercialization and pipeline development, balanced by ongoing regulatory hurdles and financial management.

Positives

• YARTEMLEA sales commenced in January 2026 and generated $28.5 million in net revenue for Q2 2026, with 73 unique accounts ordering the product by June 30, 2026.
• Net income for the quarter was $13.2 million, a substantial turnaround from a net loss of $25.4 million in Q2 2025.
• The company successfully repaid its 2026 Notes in full in February 2026.
• Significant repurchase of 2029 Notes ($30.5 million principal) was completed, reducing future interest payments and potential share dilution.
• The NIDA grant for the PDE7 inhibitor program continues to support development, with an expected in-patient clinical trial start by year-end 2026.
• The OncotoX-AML program showed promising preclinical results in nonhuman primates, with a targeted Phase 1b trial initiation in late 2027.

Negatives

• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the marketing authorization application for narsoplimab in TA-TMA, although re-examination has been requested.
• The company incurred a loss on the early extinguishment of $1.9 million related to the repurchase of 2029 Notes.
• Selling, general, and administrative expenses increased due to commercialization efforts for YARTEMLEA.
• Cash used in operating activities for the six months ended June 30, 2026 was $10.4 million.

Risks

• The EMA's negative opinion on narsoplimab for TA-TMA presents a significant regulatory hurdle for European market entry.
• The company's ability to fund future operations depends on continued commercial sales of YARTEMLEA and potentially raising additional capital.
• The valuation of the 2029 Notes embedded derivative is sensitive to stock price volatility and interest rate changes.
• The company faces ongoing risks related to clinical trial success, regulatory approvals, and market competition for its product candidates.
• The OMIDRIA contract royalty asset and obligation are subject to estimates of future royalties, which could differ from actual results.

Future Outlook

Omeros expects research and development expenses in Q3 2026 to be higher than Q2 2026, driven by increased investment in YARTEMLEA and other MASP-2 inhibitor programs, as well as the OncotoX-AML program. Selling and administrative expenses are also expected to increase in Q3 2026 due to heightened commercial activities for YARTEMLEA. Interest expense is projected to decrease in Q3 2026 due to lower outstanding principal on the 2029 Notes. Interest and other income is expected to be lower in Q3 2026, reflecting the completion of zaltenibart inventory transfers to Novo Nordisk. Income from discontinued operations is expected to be comparable to Q2 2026.

Management Comments

• "Both adult and pediatric patients with TA-TMA are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5- and C3-inhibitor regimens, in both hospital and outpatient settings."
• "By June 30, 2026, 73 unique accounts had ordered YARTEMLEA, representing a 143% increase in ordering accounts since March 31, 2026."
• "We expect to be able to start enrollment in the in-patient clinical trial [for OMS527] by year-end 2026."
• "We are targeting to initiate [a Phase 1b clinical trial for OncotoX-AML] in late 2027."
• "Omeros expects that it will be able to fund more than 12 months of operations from the date the financial statements are issued, utilizing our current cash, cash equivalents, and short-term investments, along with funds we expect to receive from commercial sales of YARTEMLEA."

Industry Context

StockSavvy.ai notes that Omeros's Q2 2026 results reflect the ongoing challenges and opportunities within the biotechnology sector, particularly for companies commercializing novel therapies. The strong initial uptake of YARTEMLEA in a niche indication like TA-TMA is a positive sign, but the EMA's negative opinion highlights the critical role of regulatory approvals in market access. The company's strategic divestiture of zaltenibart and focus on its core complement-targeting pipeline, including the PDE7 inhibitor and oncology programs, aligns with industry trends of portfolio optimization and targeted therapeutic development.

Comparison to Industry Standards

• The initial commercial sales of YARTEMLEA ($28.5 million in Q2 2026) for a rare disease indication like TA-TMA are encouraging, though direct comparisons are difficult due to the unique nature of the indication and the drug's first-in-class status. Many rare disease drugs achieve significant revenue within their first few quarters post-launch.
• The company's R&D spending as a percentage of revenue has decreased significantly following the zaltenibart sale, which is a common strategy for biotech firms to improve profitability after a major transaction or as a product matures.
• The repurchase of convertible notes ($30.5 million principal) at a premium ($60.2 million) is a strategic financial move to reduce debt burden and potential dilution, a practice seen across the industry when companies have sufficient cash flow or liquidity.
• The company's cash burn from operations ($10.4 million for H1 2026) is a key metric. While improved from the prior year, it remains a focus for investors, especially for companies in the clinical or early commercial stages.

Legal Proceedings

• As of the date of filing, Omeros Corporation was not involved in any material legal proceedings.

Stakeholder Impact

• Shareholders: The strong Q2 results, YARTEMLEA sales growth, and strategic note repurchases are positive indicators for shareholders. However, the EMA's negative opinion and the ongoing need for capital could pose risks.
• Employees: Increased SG&A expenses reflect commercialization efforts, potentially leading to growth in sales and marketing teams. Stock-based compensation remains a significant component of employee compensation.
• Creditors: The repayment of the 2026 Notes and partial repurchase of 2029 Notes reduce debt obligations, potentially improving the company's credit profile.
• Partners (Novo Nordisk, Rayner): The company continues to provide transition services to Novo Nordisk for zaltenibart. Royalty payments related to OMIDRIA are being managed according to agreements with Rayner and DRI.

Next Steps

• Finalize and prepare for presentation and publication of the health economics and outcomes research analysis for YARTEMLEA.
• Continue to educate the transplant care team regarding TA-TMA diagnostic criteria and support YARTEMLEA formulary approvals.
• Work with third-party payers to provide timely reimbursement for YARTEMLEA.
• Finalize selection of an indication for a Phase 2 clinical program for OMS1029.
• Commence nonclinical study for OMS527 and expect to start enrollment in the in-patient clinical trial by year-end 2026.
• Initiate a Phase 1b clinical trial for OncotoX-AML in late 2027.
• Continue advancing T-CAT platform toward the clinic.

Key Dates

Recommendation

Omeros demonstrates strong commercial progress with YARTEMLEA and a promising pipeline, evidenced by improved financial results and strategic debt management. However, the significant regulatory setback in Europe (EMA's negative opinion) introduces substantial uncertainty and risk. While the company has sufficient liquidity for the near term, potential future capital raises and the inherent risks of drug development warrant a cautious approach. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the EMA's re-examination process and continued commercial execution.

Keywords

Omeros Corporation, YARTEMLEA, narsoplimab, TA-TMA, complement system, biotechnology, Form 10-Q, financial results